Inventor · disambiguated record
Anrong Li
Also filed as: LI ANRONG
1 granted patent·11 pending applications·0 citations·filing 2018–2022
8Inventor score
Top patents by PatentIndex Score
12 records- 0149US2023339991A1Hypoxia-activated dna alkylating agent and medical use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 0247US2024066133A1Therapeutic agents and conjugates thereofBEIJING XUANYI PHARMASCIENCES CO LTD·Filed 2021·Application pending·0 cites
- 0346US2025387419A1Parp inhibitor-resistant patient treated with th-302ASCENTAWITS PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 0446US2023026163A1Anticancer compound and medical use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 0542US2025281514A1Treatment of cancer patients having kras mutationsASCENTAWITS PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 0640US2025304606A2A deuterated compound, and preparation method and use thereofASCENTAWITS PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 0740US2024368209A1Gemcitabine anticancer derivative and anticancer pharmaceutical useASCENTAWITS PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 0839US11773132B2Cyclic di-nucleotides as stimulator of interferon genes modulatorsBEIJING XUANYI PHARMASCIENCES CO LTD·Filed 2018·Granted Oct 3, 2023·0 cites·15 claims
- 0936US2022251021A1Akr1c3 inhibitor and medical useASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1034US2022387345A1Anti-cancer compounds acting as non-pgp substrateASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1130US2022395464A1Orally administered solid dosage form drugASCENTAWITS PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1226US2021283151A1Use of compound in drug for preventing, treating, or alleviating painASCENTAWITS PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Anrong Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →